Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Fredrik Fredh has worked on the following 10 EPO patent applications which have been published in the last five years:

EP11746252

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/32
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP11781571

SILENT FC VARIANTS OF ANTI-CD40 ANTIBODIES

IPC classification:
C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
PATENT GRANTED
EP12716629

MARKERS ASSOCIATED WITH CYCLIN-DEPENDENT KINASE INHIBITORS

IPC classification:
C12Q 1/68, G01N 33/50
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14708950

ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS

IPC classification:
A61K 39/395, C07K 14/54, C07K 16/24
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14723915

ANTIBODY DRUG CONJUGATES

IPC classification:
A61K 47/48, A61P 35/00, A61P 35/02, C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14802531

ORGANIC COMPOUNDS

IPC classification:
G01N 33/50
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14824309

LEPTIN mRNA COMPOSITIONS AND FORMULATIONS

IPC classification:
A61K 9/00, A61K 9/14, A61K 9/51, A61K 31/00, A61K 38/00, A61K 47/48
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15759938

IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2

IPC classification:
C07K 16/24
Applicant:
University of Zurich (Universit├Ąt Z├╝rich)
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15766632

ANTI-CDH6 ANTIBODY DRUG CONJUGATES

IPC classification:
A61K 31/00, A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15767598

INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES

IPC classification:
A61K 31/713, A61P 35/00, C12N 15/113, G01N 33/574
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature